SCHEMBL21534089

SCHEMBL21534089

CSC(C)n1cnc2cnccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.44
JAK2 O60674 3/20 0.38
JAK3 P52333 3/20 0.38
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
USP2 O75604 1/20 0.35
HTT P42858 1/20 0.35
NCOA1 Q15788 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35
HCAR3 P49019 1/20 0.34
LTA4H P09960 1/20 0.33
ATM Q13315 1/20 0.33
MKNK1 Q9BUB5 1/20 0.32
MKNK2 Q9HBH9 1/20 0.32
NFATC1 O95644 1/20 0.32
GSK3B P49841 1/20 0.32
DYRK1A Q13627 1/20 0.32
ALDH1A1 P00352 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1106481 0.83 FGFR1 (0.49) FGFR1JAK2JAK3HPGDHSD17B10
SCHEMBL1701476 0.73 FGFR1 (0.49) FGFR1JAK2JAK3HPGDHSD17B10
SCHEMBL29593970 0.70 FGFR1 (0.53) FGFR1JAK2JAK3HPGDHSD17B10
SCHEMBL256337 0.70 FGFR1 (0.53) FGFR1JAK2JAK3HPGDHSD17B10
SCHEMBL1106468 0.69 NFATC1 (0.45) FGFR1JAK2JAK3HPGDHSD17B10
SCHEMBL12763767 0.69 POLB (0.53) FGFR1JAK2JAK3USP2HTT
SCHEMBL1743206 0.67 ADA (0.63) HSD17B10ALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL20083791 0.67 CYP3A4 (0.40) GSK3BALDH1A1SMN1; SMN2
SCHEMBL14021996 0.67 LTA4H (0.49) FGFR1JAK2JAK3HPGDHSD17B10
SCHEMBL25291568 0.66 FGFR1 (0.53) FGFR1JAK2JAK3HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10464960-B2 Salen complexes with dianionic counterions SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) 2019-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10464960-B2 Salen complexes with dianionic counterions NCLN, POLN, NCL FGFR1 4530/4885JAK2 3383/4885JAK3 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.